https://www.selleckchem.com/products/dnqx.html
05), PFS (median 6.7 versus 2.4 months, P.01), and OS (median not reached versus 6.0 months, P=.01). In aNSCLC patients, statin use was associated with improved ORR (40% versus 22%, P=.04) and PFS (median 7.8 versus 3.6 months, P=.03), but no significant difference in OS was found (median 13.1 versus 10.1 months, P=.3. Multivariable analysis confirmed the correlation between statin use and better PFS and OS in MPM and better PFS in aNSCLC. In the whole cohort, high but not low/moderate-intensity statins were associated with better OS
Like
Comment
Share
